Akeso's Ligufalimab Combination Shows Deep Responses And Survival Benefit In Frontline AML

Akeso reported Phase II data showing its CD47-targeting antibody Ligufalimab delivered meaningful survival and response improvements in treatment-naïve acute myeloid leukemia. The update, presented at the 2026 European Hematology Association oral session, is a positive clinical milestone for the program and supports the drug’s development outlook. The readout is encouraging for the company, though near-term market impact is likely limited to the stock rather than the broader sector.

Analysis

Akeso reported Phase II data showing its CD47-targeting antibody Ligufalimab delivered meaningful survival and response improvements in treatment-naïve acute myeloid leukemia. The update, presented at the 2026 European Hematology Association oral session, is a positive clinical milestone for the program and supports the drug’s development outlook. The readout is encouraging for the company, though near-term market impact is likely limited to the stock rather than the broader sector.